EGFR and cancer: These studies indicated that CAPN1 affect a variety of malignant tumors as a tumor promoter, and these evidences pointed to the effects of CAPN1 on drug resistance and molecular phosphorylation activity, which arouses our interest in the question of what role CAPN1 plays in LUAD EGFR‐TKI and malignant behavior.